Science 37  Science 37 is an American clinical research company. Science 37 was founded in 2014 by company CEO Noah Craft and Chief Medical Officer Belinda Tan, working out of LA BioMed at Harbor-UCLA Medical Center. It received its initial round of funding in 2015, with a $6.5 million investment. In 2016 the company’s second round of financing resulted in $31 million in funding, and a 2017 round of financing resulted in $29 million. Science 37 has developed the Network Oriented Research Assistant platform, also known as the NORA platform, which includes video chat, digital self-photography, data collection, and electronic consent. Together, these features are used to conduct “site-less” trials. The platform also aids researchers in finding and contacting potential participants, and scheduling trial participants for in-home activities like questionnaires, mobile nurse visits, and door-step study medicine delivery. In 2015 Science 37 began working with Genentech in the recruitment of trial participants. In 2017 Science 37 then completed a site-less trial for AOBiome Therapeutics. This was the first “interventional, randomized, placebo-controlled trial” to be completed virtually. That year Science 37 also began planning site-less trials for Sanofi and Otsuka Pharmaceutical. In 2018 the company partnered with Novartis to plan several site-less clinical trials. Novartis also owns 10% of Science 37 from an early-stage investment in the company. Science 37 was already in the process of conducting trials with Novartis in acne, cluster headaches, and fatty liver disease.